Cyclacel Pharmaceuticals (CYCC, Financial) has reported that it is unaware of any significant changes in its business operations or financial status that would explain the recent fluctuations in its stock price and trading volume observed on July 15, 2025. The company reassured stakeholders that there have been no adverse shifts in its operational outcomes, strategic direction, or future outlook, beyond what has already been publicly disclosed. This includes an amendment to their Exchange Agreement with FITTERS Diversified Berhad, which was announced on July 7, 2025.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Cyclacel Pharmaceuticals Inc (CYCC, Financial) is $1.00 with a high estimate of $1.00 and a low estimate of $1.00. The average target implies an downside of 91.89% from the current price of $12.33. More detailed estimate data can be found on the Cyclacel Pharmaceuticals Inc (CYCC) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Cyclacel Pharmaceuticals Inc's (CYCC, Financial) average brokerage recommendation is currently 3.0, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
